PRKCD and chronic myelogenous leukemia, BCR-ABL1 positive: We also demonstrated that the inhibition of PKCδ could synergize with any of the three generations of TKIs to potentiate CML cell death and decrease the clonogenic potential of CML-CD34+ cells.